Skip to main content
PMC home page
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
. 2003 Feb;20(2):82–90. doi: 10.1023/A:1021792125123

Low Molecular Weight Heparin in Immunological Recurrent Abortion—The Incredible Cure

Gautam N Allahbadia 1, Swati G Allahbadia 2
PMCID: PMC3455788  PMID: 12688592

Abstract

The most compelling association between pregnancy loss and autoimmune phenomena has been with the presence of antiphospholipid antibodies (APA)—lupus anticoagulant and anticardiolipin antibody. The ‘antiphospholipid antibody syndrome’ has been described in women with a history of recurrent pregnancy loss or thrombosis with positive APA or lupus anticoagulant on two occasions. Although several treatments have been advocated, heparin and aspirin treatment is emerging as the treatment of choice for the APA syndrome associated with recurrent pregnancy loss. The rationale for prescribing aspirin in cases of recurrent reproductive failure associated with APA seropositivity is that aspirin may counter APA-mediated hypercoagulability in the choriodecidual space, a situation which if left unaddressed would traumatize the trophoblast and compromise feto-maternal exchange. Heparin on the other hand, through preventing APA from interfering with syncytialization of the early cytotrophoblast and by countering APA interference with phospholipid-decidual reactions that are vital to early implantation, might potentially promote both early implantation and subsequent placentation.

Keywords: Low molecules weight heparin, recurrent abortion, antiphospholipid antibodies

Full Text

The Full Text of this article is available as a PDF (73.2 KB).

References

  • 1.Edmonds DK, Lindsay KI, Miller JF. Early embryonic mortality in women. Fertil Steril. 1982;38:447–453. [PubMed] [Google Scholar]
  • 2.Alberman E. The epidemiology of repeated abortion. In: Sharp F, Beard RW, editors. Early Pregnancy Loss: Mechanisms and Treatment. New York: Springer; 1988. pp. 9–17. [Google Scholar]
  • 3.Stray-Pederson B, Stray-Pederson S. Etiological factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol. 1984;148:140–146. doi: 10.1016/s0002-9378(84)80164-7. [DOI] [PubMed] [Google Scholar]
  • 4.Hill JA. Immunological mechanisms of pregnancy maintenance and failure: A critique of theories and therapy. Am J Reprod Immunol. 1990;22:1–12. doi: 10.1111/j.1600-0897.1990.tb01029.x. [DOI] [PubMed] [Google Scholar]
  • 5.Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92:156–159. doi: 10.7326/0003-4819-92-2-156. [DOI] [PubMed] [Google Scholar]
  • 6.Gastineau DA, Keizmer FS, Nichols WL. Lupus anticoagulant: An analysis of the clinical and Laboratory features of 219 cases. Am J Hematol. 1985;19:265–275. doi: 10.1002/ajh.2830190308. [DOI] [PubMed] [Google Scholar]
  • 7.Harris EN, Chan JKH, Asherson RA. Thrombosis, recurrent fetal loss and thrombocytopenia: Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986;146:2153–2159. [PubMed] [Google Scholar]
  • 8.Cowchock FS: The role of antiphospholipid antibodies in obstetric medicine. In Current Obstetric Medicine, RV Lee (ed), Mosby-Yearbook, St Louis, MO, pp 229–247
  • 9.Lockwood C, Reece LA, Roniero LT, Hobbins JC. Antiphospholipid antibody and pregnancy wastage. Lancet. 1986;ii:742–743. doi: 10.1016/s0140-6736(86)90252-7. [DOI] [PubMed] [Google Scholar]
  • 10.Gleicher N, Pratt D, Dudkiewicz A. What do we really know about autoantibody abnormalities and reproductive failure: A critical review. Autoimmunity. 1993;16:115–140. doi: 10.3109/08916939308993318. [DOI] [PubMed] [Google Scholar]
  • 11.Rai RS, Regan L, Clifford K, Pickering W, Dave M, Mackie I. Antiphospholipid antibodies and β-2 glycoprotein-I in 500 women with recurrent miscarriage: Results of a comprehensive screening approach. Hum Reprod. 1995;10:101–105. doi: 10.1093/oxfordjournals.humrep.a136224. [DOI] [PubMed] [Google Scholar]
  • 12.Balasch J, Creus M, Fábrogues F. Antiphospholipid antibodies and human reproductive failure. Hum Reprod. 1996;11:2310–2315. doi: 10.1093/oxfordjournals.humrep.a019095. [DOI] [PubMed] [Google Scholar]
  • 13.Hatasaka HH, Branch DW, Kutteh W, Scott JR. Autoantibody screening for infertility: Explaining the unexplained? J Reprod Immunol. 1997;34:137–153. doi: 10.1016/s0165-0378(97)00027-2. [DOI] [PubMed] [Google Scholar]
  • 14.Balasch J, Font J. Antiphospholipid antibody testing in patients with pregnancy loss. Lupus. 1994;3:429–431. doi: 10.1177/096120339400300512. [DOI] [PubMed] [Google Scholar]
  • 15.Balasch J. Immunological factors in pregnancy wastage: Truth or fiction. In: Asch R, Studd JWW, editors. Progress in Reproductive Medicine. London: Parthenon; 1995. pp. 117–138. [Google Scholar]
  • 16.Rai RS, Cohen H, Regan L.Non-pregnant women with a history of recurrent miscarriage are in a pro-thrombotic state Hum Reprod 19961127–29.9147099 [Google Scholar]
  • 17.Panton IA, Kilpatrick DC. Anti-cardiolipin antibodies in sexual partners of recurrent aborters. Hum Reprod. 1997;12:464–467. doi: 10.1093/humrep/12.3.464. [DOI] [PubMed] [Google Scholar]
  • 18.El-Roeiy A, Dmowski WP, Gleicher N. Danazol but not gonadotrophin-releasing hormone agonists suppress autoantibodies in endometriosis. Fertil Steril. 1988;50:864–871. doi: 10.1016/s0015-0282(16)60363-1. [DOI] [PubMed] [Google Scholar]
  • 19.E1-Roeiy A, Gleicher N. Definition of normal autoantibody levels in an apparently healthy population. Obstet Gynecol. 1988;77:596–602. [PubMed] [Google Scholar]
  • 20.Ober C, Kamson T, Harcowe L. Autoantibodies and pregnancy history in a healthy population. Am J Obstet Gynecol. 1993;169:143–147. doi: 10.1016/0002-9378(93)90150-h. [DOI] [PubMed] [Google Scholar]
  • 21.Moulias R, Proust J, Wanga A. Age related increase in autoantibodies. Lancet. 1984;i:178–1129. doi: 10.1016/s0140-6736(84)92547-9. [DOI] [PubMed] [Google Scholar]
  • 22.Shoenfeld Y, Segol G, Segol D. Detection of antibodies to total bistones and their subfraction in systemic lupus erythematosus patients and their asymptomatic relatives. Arthritis Rheumatica. 1987;30:169–175. doi: 10.1002/art.1780300207. [DOI] [PubMed] [Google Scholar]
  • 23.Gleicher N, Luih C, Dudkiewicz A. Autoantibody profiles and immunoglobulin levels as predictors of in vitro fertilization success. Am J Obstet Gynecol. 1994;170:1145–1149. doi: 10.1016/s0002-9378(94)70110-5. [DOI] [PubMed] [Google Scholar]
  • 24.El-Roeiy A, Gleicher N, Fribert T. Correlation between peripheral blood and follicular fluid autoantibodies and impact on in vitro fertilization. Obstet Gynecol. 1987;70:163–170. [PubMed] [Google Scholar]
  • 25.Gleicher N, El-Roeiy A, Carfino E, Fnberg J. Reproductive failure because of autoantibodies: Unexplained infertility and pregnancy wastage. Am J Obstet. Gynecol. 1989;160:1376–1380. doi: 10.1016/0002-9378(89)90858-2. [DOI] [PubMed] [Google Scholar]
  • 26.Geva F, Yaron V, Lessing JB. Circulatory autoimmune antibodies may be responsible for implantation failure in in-vitro fertilization. Fertil Steril. 1994;62:802–806. doi: 10.1016/s0015-0282(16)57008-3. [DOI] [PubMed] [Google Scholar]
  • 27.El-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1991;164:1253–1261. doi: 10.1016/0002-9378(91)90695-n. [DOI] [PubMed] [Google Scholar]
  • 28.Kajino T. Polyclonal activation of 1gM antibodies to phospholipids in patients with idiopathic growth retardation. Am J Reprod. Immunol. 1991;28:231–234. doi: 10.1111/j.1600-0897.1991.tb01060.x. [DOI] [PubMed] [Google Scholar]
  • 29.Polzin WJ, Kopelman JN, Robinson RD. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth retardation. Obstet Gynecol. 1991;78:1108–1111. [PubMed] [Google Scholar]
  • 30.Out HJ, Bruinse HW, Christiaens GCML. A prospective, controlled multicenter study on obstetric risk of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992;167:26–32. doi: 10.1016/s0002-9378(11)91619-6. [DOI] [PubMed] [Google Scholar]
  • 31.Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of th association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–559. doi: 10.1016/0029-7844(95)00247-o. [DOI] [PubMed] [Google Scholar]
  • 32.Lockshin RD, Druzin ML, Goei S. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985;313:152–156. doi: 10.1056/NEJM198507183130304. [DOI] [PubMed] [Google Scholar]
  • 33.Tan SL, Doyle P, Campbell S. Obstetric outcome of in vitro fertilization pregnancies compared with normally conceived pregnancies. Am J Obstet Gynecol. 1992;167:773–784. doi: 10.1016/s0002-9378(11)91589-0. [DOI] [PubMed] [Google Scholar]
  • 34.Nurat P, Olivennes F, de Muzon J. Task force report on the outcome of pregnancies and children conceived by in vitro fertilization (France: 1987 to 1989) Fertil Steril. 1994;61:324–330. [PubMed] [Google Scholar]
  • 35.Olivennes F, Kadhel P, Rufat P. Perinatal outcome of twin pregnancies obtained after in vitro fertilization: Comparison with twin pregnancies obtained spontaneously after ovarian stimulation. Fertil Steril. 1996;66:105–109. doi: 10.1016/s0015-0282(16)58395-2. [DOI] [PubMed] [Google Scholar]
  • 36.Harris EN. Special report. The second international anti-cardiolipin standardization workshop/the Kingston Anti-phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol. 1990;94:476–84. doi: 10.1093/ajcp/94.4.476. [DOI] [PubMed] [Google Scholar]
  • 37.Lockshin MD. Antiphospholipid antibody syndrome. JAMA. 1992;268:451–1453. [PubMed] [Google Scholar]
  • 38.Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166:1318–23. doi: 10.1016/0002-9378(92)91596-3. [DOI] [PubMed] [Google Scholar]
  • 39.Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low dose aspirin is superior to low dose aspirin. Am J Obstet Gynecol. 1996;174:1584–1589. doi: 10.1016/s0002-9378(96)70610-5. [DOI] [PubMed] [Google Scholar]
  • 40.Raziel A, Herman A, Bukovsky I. Intravenous immunoglobulin treatment of pregnant patients with unexplained recurrent abortions. Hum Reprod. 1996;11:711–715. doi: 10.1093/oxfordjournals.humrep.a019238. [DOI] [PubMed] [Google Scholar]
  • 41.Bronson R. Editorial: Immunology and reproductive medicine. Hum Reprod. 1995;10:755–757. doi: 10.1093/oxfordjournals.humrep.a136029. [DOI] [PubMed] [Google Scholar]
  • 42.Branch DW, Silver RM, Blackwell LL. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience. Obstet Gynecol. 1992;80:614–620. [PubMed] [Google Scholar]
  • 43.Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other phospholipid antibodies. Blood. 1994;89:2854–2867. [PubMed] [Google Scholar]
  • 44.Gleicher N, Liu H, Dudkiewicz A. Autoantibody profiles and immunoglobulin levels as predictors of IVF success. Am J Obstet Gynecol. 1994;170:1145–1149. doi: 10.1016/s0002-9378(94)70110-5. [DOI] [PubMed] [Google Scholar]
  • 45.Birdsall MA, Lockwood GM, Ledger WL. Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod. 1996;11:1185–1189. doi: 10.1093/oxfordjournals.humrep.a019352. [DOI] [PubMed] [Google Scholar]
  • 46.Sessions A, Horowitz AF. Differentiation-related difference in the plasma membrane phospholipid asymmetry of myogenic and firbrogenic cells. Biochim Biophys Acta. 1982;728:103–111. doi: 10.1016/0005-2736(83)90442-x. [DOI] [PubMed] [Google Scholar]
  • 47.Rote NS, Walter A, Lyden TW. Antiphospholipid antibodies–lobsters or red herrings? Am J Reprod Immunol. 1992;28:31–7. doi: 10.1111/j.1600-0897.1992.tb00753.x. [DOI] [PubMed] [Google Scholar]
  • 48.Sher G, Feinman M, Zouves C. High fecundity rates following in-vitro fertilization and embryo transfer in anti-phospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod. 1994;9:2278–2283. doi: 10.1093/oxfordjournals.humrep.a138437. [DOI] [PubMed] [Google Scholar]
  • 49.Kowalik A, Vichnin M, Branch W, Berkeley A: Mid-follicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with IVF outcome. American Society of Reproductive Medicine Meeting, November 1996, Boston, MA, USA. Abstract P-130
  • 50.Ermel LD, Marshbum PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from serum of women with recurrent pregnancy loss (RPL) Am J Reprod Immunol. 1995;33:14–20. doi: 10.1111/j.1600-0897.1995.tb01133.x. [DOI] [PubMed] [Google Scholar]
  • 51.Patrono C. Aspirin as an antiplatelet drug. N Eng J Med. 1994;330:1287–1294. doi: 10.1056/NEJM199405053301808. [DOI] [PubMed] [Google Scholar]
  • 52.Hauth JL. Low-dose aspirin: Lack of association with an increase in abruptio placentae or perinatal mortality. Obstet Gynecol. 1995;85:1055–1058. doi: 10.1016/0029-7844(95)00042-p. [DOI] [PubMed] [Google Scholar]
  • 53.Malathy PV, Cheng HC, Dey SE. Production of leukotrienes and prostaglandins in the rat uterus during preimplantation period. Prostaglandins. 1986;32:605–614. doi: 10.1016/0090-6980(86)90042-0. [DOI] [PubMed] [Google Scholar]
  • 54.Hoffman LH, Davenport GR, Brash AR. Endometrial prostaglandins and phospholipase activity related to implantation in rabbits: Effects of dexamethasone. Biol Reprod. 1984;38:544–555. doi: 10.1095/biolreprod30.3.544. [DOI] [PubMed] [Google Scholar]
  • 55.Johnston JM, Bleasdale JE, Hoffman DR. Functions of PAF in reproduction and development: involvement of PAF in fetal lung maturation and parturition. In: Synyer F, editor. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum; 1987. p. 375. [Google Scholar]
  • 56.O'Neill C. Embryo-derived platelet activating factor: A preimplantation embryo mediator of maternal recognition of pregnancy. Domest Anim Endocrinol. 1987;4:69–85. doi: 10.1016/0739-7240(87)90001-4. [DOI] [PubMed] [Google Scholar]
  • 57.O'Neill C, Gidley-Baird AA, Pike JL, Porter RN, Sinosich MJ, Saunders DM. Maternal blood platelet physiology and luteal phase endocrinology as a means of monitoring pre and postimplantation embryo viability following in vitro fertilization. J In Vitro Fertil Embryo Transfer. 1985;2:87–93. doi: 10.1007/BF01139339. [DOI] [PubMed] [Google Scholar]
  • 58.Holmes PV, Sjogren A, Hamberger L. Prostaglandin-E2 released by preimplantation human conceptuses. J Reprod Immunol. 1989;17:79–86. doi: 10.1016/0165-0378(90)90041-4. [DOI] [PubMed] [Google Scholar]
  • 59.van der Welden RMF, Helmerhorst FM, Keirse MJNC. Influence of prostaglandins and platelet activating factor on implantation. Hum Reprod. 1991;6:436–442. [PubMed] [Google Scholar]
  • 60.Sessions A, Horowitz AF. Myoblast aminophospholipid asymmetry differs from that of fibroblasts. FEBS. 1981;34:75–78. doi: 10.1016/0014-5793(81)80554-6. [DOI] [PubMed] [Google Scholar]
  • 61.Rauch J, Janoff AS. Phospholipid in the hexagonal 11 phase is immunogenic: Evidence for immunorecognition of nonbilayer lipid phases in vivo. Proc Nazi Acad Sci USA. 1990;87:4112–4114. doi: 10.1073/pnas.87.11.4112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Asch RH. High pregnancy rates after oocyte and embryo donation. Hum Reprod. 1993;7:734. [PubMed] [Google Scholar]
  • 63.Fisch B, Rikover Y, Shohat L, Zurgil N, Tadir Y, Ovadia J, Wik I, Yron I. The relationship between in vitro fertilization and naturally occurring antibodies: Evidence for increased production of antiphospholipid antibodies. Fertil Steril. 1991;56(4):718–724. doi: 10.1016/s0015-0282(16)54605-6. [DOI] [PubMed] [Google Scholar]
  • 64.Schwartz M, Jewelewicz R. The use of gonadotrophins for induction of ovulation. Fertil Steril. 1991;35:3. doi: 10.1016/s0015-0282(16)45249-0. [DOI] [PubMed] [Google Scholar]
  • 65.Scialli AR. The reproductive toxicity of ovulation induction. Fertil Steril. 1986;45:315. doi: 10.1016/s0015-0282(16)49209-5. [DOI] [PubMed] [Google Scholar]
  • 66.McIntyre JA, Taylor CG, Torry DS, Wagenknecht DR, Wilson J, Faulk WP. Heparin and pregnancy in women with a history of repeated miscarriages. Haemostasis. 1993;23(Suppl1):202–211. doi: 10.1159/000216929. [DOI] [PubMed] [Google Scholar]
  • 67.Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid antibodies. Clin Rheum Dis. 1985;11:591–609. [PubMed] [Google Scholar]
  • 68.Matzner W, Chong F, Xu HF, Chung W. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. J Reprod Med. 1994;39:27–30. [PubMed] [Google Scholar]
  • 69.Jewolf F, Carreras LO, Moennan P. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol. 1982;142:829–834. doi: 10.1016/s0002-9378(16)32527-3. [DOI] [PubMed] [Google Scholar]
  • 70.Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol. 1991;41:179–186. doi: 10.1016/0028-2243(91)90021-c. [DOI] [PubMed] [Google Scholar]
  • 71.Lyden TW, Vogt E, Ng AK. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J. Reprod Immunol. 1992;22:1–14. doi: 10.1016/0165-0378(92)90002-l. [DOI] [PubMed] [Google Scholar]
  • 72.Katsuragawa H, Kanzaki H, Inoue T. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod. 1997;56:50–58. doi: 10.1095/biolreprod56.1.50. [DOI] [PubMed] [Google Scholar]
  • 73.Tartakovsky B, Bermas BL, Sthoeger Z. Defective maternal—fetal interaction in a murine autoimmune model. Hum Reprod. 1996;11:2408–2411. doi: 10.1093/oxfordjournals.humrep.a019125. [DOI] [PubMed] [Google Scholar]
  • 74.Kowalik A, Viehnin M, Li HC, Branch W, Berkeley A. Mid-follicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome. Fertil Steril. 1997;68:298–304. doi: 10.1016/s0015-0282(97)81519-1. [DOI] [PubMed] [Google Scholar]
  • 75.Cowchock S, Reece EA. For the Organizing Group of the Antiphospholipid Antibody Treatment Trial. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol. 1997;176:1099–1100. doi: 10.1016/s0002-9378(97)70409-5. [DOI] [PubMed] [Google Scholar]
  • 76.Clark DA. Current concepts of immunoregulation of implantation. In: Chapman M, Grudzinskas G, Chard T, editors. Implantation: Biological and Clinical Aspects. London: Springer; 1989. pp. 163–175. [Google Scholar]
  • 77.Birkenfeld A, Mukaida T, Minichiello L. Incidence of autoimmune antibodies in failed embryo transfer cycles. Am J Reprod Immunol. 1994;31:65–68. doi: 10.1111/j.1600-0897.1994.tb00848.x. [DOI] [PubMed] [Google Scholar]
  • 78.Geva E, Amit A, Lemer-Geva L. Autoimmune disorders: Another possible cause for in-vitro fertilization and embryo transfer failure. Hum Reprod. 1995;10:2560–2563. doi: 10.1093/oxfordjournals.humrep.a135745. [DOI] [PubMed] [Google Scholar]
  • 79.Kaider B, Price DL, Rouses RG, Coulam CR. Antiphospholipid antibody prevalence in patients in an IVF program. J Reprod Immunol. 1996;35:388–393. doi: 10.1111/j.1600-0897.1996.tb00499.x. [DOI] [PubMed] [Google Scholar]
  • 80.Rai R, Regan L. Antiphospholipid antibodies in women undergoing in-vitro fertilization. Hum Reprod. 1997;12:197–198. doi: 10.1093/humrep/12.1.197. [DOI] [PubMed] [Google Scholar]
  • 81.Di Simone N, Caliandro D, Castellani R, Freazzani G, Carolis S, Caruso A. Low molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Hum Reprod. 1999;14:489–495. doi: 10.1093/humrep/14.2.489. [DOI] [PubMed] [Google Scholar]
  • 82.Di Simone N, Ferrazzani S, Castellani R. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod. 1997;12:2061–2065. doi: 10.1093/humrep/12.9.2061. [DOI] [PubMed] [Google Scholar]
  • 83.Rand JH, Wu XX, Andree HAM. Pregnancy loss in the antiphospholipid antibody syndrome: A possible thrombogenic mechanism. N Engl J Med. 1997;337:154–160. doi: 10.1056/NEJM199707173370303. [DOI] [PubMed] [Google Scholar]
  • 84.Mcintyre JA, Wagenknecht DR. Interaction of heparin with beta2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb Res. 1992;68:495–500. doi: 10.1016/0049-3848(92)90063-g. [DOI] [PubMed] [Google Scholar]
  • 85.Kutteh WH, Ermel LD. A clinical trial for the treatment of aPL associated RPL with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35:402–407. doi: 10.1111/j.1600-0897.1996.tb00501.x. [DOI] [PubMed] [Google Scholar]
  • 86.Dawes J, Bara L, Billaud E. Relationship between biological activity and concentration of a low molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis. 1986;16:116–122. doi: 10.1159/000215281. [DOI] [PubMed] [Google Scholar]
  • 87.Dulitzki M, Pauzner R, Langevitz P. Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol. 1996;87:380–383. doi: 10.1016/0029-7844(95)00452-1. [DOI] [PubMed] [Google Scholar]
  • 88.Ginsberg JS, Hirsch J. Use of antithrombotic agents during pregnancy. Chest. 1995;108:305S–311S. doi: 10.1378/chest.108.4_supplement.305s. [DOI] [PubMed] [Google Scholar]
  • 89.Bara L, Billaud E, Garamond G, Kher H. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631–636. doi: 10.1016/0049-3848(85)90244-0. [DOI] [PubMed] [Google Scholar]
  • 90.Bara L, Samana M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 1988;543:65–72. [PubMed] [Google Scholar]
  • 91.Monreal M, Lafoz E, Olive A. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to Coumarin. Thromb Hemost. 1994;71:7–11. [PubMed] [Google Scholar]
  • 92.Shefras J, Farquarson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol. 1996;65:171–174. doi: 10.1016/0301-2115(95)02358-5. [DOI] [PubMed] [Google Scholar]
  • 93.Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (Cy216) does not cross the placenta during the third trimester of pregnancy. Thromb Hemost. 1987;57:234–239. [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES